Zhejiang Medicine (600216.SH) Plans to Spin Off Subsidiary Xinkang Biotech for HKEX Listing

Stock News11-26

Zhejiang Medicine Co., Ltd. (600216.SH) announced plans to spin off its subsidiary, Zhejiang Xinkang Biopharmaceutical Co., Ltd. ("Xinkang Biotech"), for a potential listing on the Hong Kong Stock Exchange (HKEX). The move aims to enhance the development of the company's biopharmaceutical segment, optimize resource allocation through capital markets, and expand financing channels to improve overall profitability and competitiveness.

If implemented, the spin-off will not result in Zhejiang Medicine losing control of Xinkang Biotech. The company emphasized that the listing would not adversely affect its other business operations, sustained profitability, or independent listing status.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1110403807?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110403807","market":"fut","top_or_hot":-1,"title":"Zhejiang Medicine (600216.SH) Plans to Spin Off Subsidiary Xinkang Biotech for HKEX Listing","media":"Stock News","content":"<p>Zhejiang Medicine Co., Ltd. (600216.SH) announced plans to spin off its subsidiary, Zhejiang Xinkang Biopharmaceutical Co., Ltd. (\"Xinkang Biotech\"), for a potential listing on the Hong Kong Stock Exchange (HKEX). The move aims to enhance the development of the company's biopharmaceutical segment, optimize resource allocation through capital markets, and expand financing channels to improve overall profitability and competitiveness.</p>\n<p>If implemented, the spin-off will not result in Zhejiang Medicine losing control of Xinkang Biotech. The company emphasized that the listing would not adversely affect its other business operations, sustained profitability, or independent listing status.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Medicine (600216.SH) Plans to Spin Off Subsidiary Xinkang Biotech for HKEX Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Medicine (600216.SH) Plans to Spin Off Subsidiary Xinkang Biotech for HKEX Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-26 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Medicine Co., Ltd. (600216.SH) announced plans to spin off its subsidiary, Zhejiang Xinkang Biopharmaceutical Co., Ltd. (\"Xinkang Biotech\"), for a potential listing on the Hong Kong Stock Exchange (HKEX). The move aims to enhance the development of the company's biopharmaceutical segment, optimize resource allocation through capital markets, and expand financing channels to improve overall profitability and competitiveness.</p>\n<p>If implemented, the spin-off will not result in Zhejiang Medicine losing control of Xinkang Biotech. The company emphasized that the listing would not adversely affect its other business operations, sustained profitability, or independent listing status.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1110403807","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110403807","pubTimestamp":1764150854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Medicine Co., Ltd. (600216.SH) announced plans to spin off its subsidiary, Zhejiang Xinkang Biopharmaceutical Co., Ltd. (\"Xinkang Biotech\"), for a potential listing on the Hong Kong Stock...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600216":"浙江医药","BK0188":"融资融券","BK0191":"维生素","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"浙江医药(600216.SH)拟分拆子公司新康生物港交所上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600216":1},"content_text":"Zhejiang Medicine Co., Ltd. (600216.SH) announced plans to spin off its subsidiary, Zhejiang Xinkang Biopharmaceutical Co., Ltd. (\"Xinkang Biotech\"), for a potential listing on the Hong Kong Stock Exchange (HKEX). The move aims to enhance the development of the company's biopharmaceutical segment, optimize resource allocation through capital markets, and expand financing channels to improve overall profitability and competitiveness.\nIf implemented, the spin-off will not result in Zhejiang Medicine losing control of Xinkang Biotech. The company emphasized that the listing would not adversely affect its other business operations, sustained profitability, or independent listing status.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1110403807","isCrawlerRequest":true}